In mouse syngeneic tumor models, genetic ablation of the IFN-alpha receptor (IFNAR1) in DCs demonstrated that type I IFN signaling in DCs, and particularly the cDC1 subset, is required for IFN’s anti-tumor activity (9, 11). Here, IFNAR1 is linked to neoplasm.